Invus Global Management, LLC - 02 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: LXRX
Reported as of: 02 Feb 2026
Net transaction value: +$54,984,433
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:25:05 UTC
Prior SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: See Exhibit 99.1

Key filing fact

Invus Global Management, LLC filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 04 Feb 2026.

Key facts

This page summarizes Invus Global Management, LLC's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
4 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Feb 2026, 16:25.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: +$54,984,433.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (9)

CIK 0002005369 Primary reporting owner

Invus Global Management, LLC

Relationship: Director, 10%+ Owner
Address: 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK
Signature: See Exhibit 99.1
Signature date: 04 Feb 2026

CIK 0002005245

Siren, L.L.C.

Relationship: Director, 10%+ Owner
Address: C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE 30TH FLOOR, NEW YORK
Signature: See Exhibit 99.1
Signature date: 04 Feb 2026

CIK 0001053890

DEBBANE RAYMOND

Relationship: Director
Address: C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE 30TH FLOOR, NEW YORK
Signature: See Exhibit 99.1
Signature date: 04 Feb 2026

CIK 0002048403

Artal Participations S.a r.l.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 04 Feb 2026

CIK 0001218180

Artal International S.C.A.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 04 Feb 2026

CIK 0001522131

Artal International Management S.A.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 04 Feb 2026

CIK 0001053906

Artal Group S.A.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 04 Feb 2026

CIK 0001283968

Westend S.A.

Relationship: Director, 10%+ Owner
Address: VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG, LUXEMBOURG
Signature: See Exhibit 99.1
Signature date: 04 Feb 2026

CIK 0001460840

Stichting Administratiekantoor Westend

Relationship: Director, 10%+ Owner
Address: H.J.E. WENCKEBACHWEG 252, AMSTERDAM, NETHERLANDS
Signature: See Exhibit 99.1
Signature date: 04 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXRX transaction

Common Stock

Award

Transaction value: $24,120,000
Shares: +18,553,846
Change %: +14%
Price: $1.30
Shares after: 154,734,327
Date: 02 Feb 2026
Ownership: See Footnotes
Footnotes: F1, F4, F9, F15

LXRX transaction

Common Stock

Award

Transaction value: $5,000,000
Shares: +3,846,154
Change %: +109%
Price: $1.30
Shares after: 7,362,368
Date: 02 Feb 2026
Ownership: See Footnotes
Footnotes: F1, F5, F10, F15

LXRX transaction

Common Stock

Purchase

Transaction value: $2,000,001
Shares: +1,538,462
Change %
Price: $1.30
Shares after: 1,538,462
Date: 02 Feb 2026
Ownership: See Footnotes
Footnotes: F2, F6, F11, F15

LXRX transaction

Series B Convertible Preferred Stock

Award

Transaction value: $23,864,433
Shares: +367,145
Change %
Price: $65.00
Shares after: 367,145
Date: 02 Feb 2026
Ownership: See Footnotes
Footnotes: F3, F4, F9, F15

LXRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 35,402,689
Date: 02 Feb 2026
Ownership: See Footnotes
Footnotes: F7, F12, F15

LXRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 5,451,204
Date: 02 Feb 2026
Ownership: See Footnotes
Footnotes: F8, F13, F15

LXRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,385,689
Date: 02 Feb 2026
Ownership: See Footnotes
Footnotes: F14, F15

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 15 footnotes

Footnote F1

On January 29, 2026, Artal Participations S.a r.l. entered into a purchase agreement with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 22,400,000 shares of common stock par value $0.001 per share (the "Common Stock") of the Issuer at a price of $1.30 per share (the "Purchase Price"). On January 30, 2026, Artal Participations S.a r.l. assigned its right to purchase from the Issuer 3,846,154 shares of Issuer Common Stock to Invus Public Equities, L.P., and Invus Public Equities, L.P. agreed to purchase directly from the Issuer 3,846,154 shares of Issuer Common Stock at the Purchase Price. The purchase closed on February 2, 2026.

Footnote F2

On February 2, 2026, Avicenna Life Sci Master Fund LP purchased 1,538,462 shares of Common Stock as part of the Issuer's underwritten public offering.

Footnote F3

On January 29, 2026, Artal Participations S.a r.l. entered into a preferred stock purchase agreement (the "Preferred Purchase Agreement") with the Issuer pursuant to which Artal Participations S.a r.l. agreed to purchase 367,145.12 shares of Series B Convertible Preferred Stock, par value $0.01 per share (the "Preferred Stock") of the Issuer at a price of $65.00 per share. The Preferred Purchase Agreement also provides Artal Participations S.a r.l. the right to purchase from the Issuer, up to an additional 94,854.88 shares of Preferred Stock at a price per share of $65.00. Each share of Preferred Stock will automatically convert into 50 shares of the Issuer's Common Stock upon receipt of shareholder approval and the satisfaction of certain other conditions; however, absent the satisfaction of such conditions, the shares are not convertible. The purchase closed on February 2, 2026.

Footnote F4

These securities are directly held by Artal Participations S.a r.l.

Footnote F5

These securities are directly held by Invus Public Equities, L.P.

Footnote F6

These securities are directly held by Avicenna Life Sci Master Fund LP

Footnote F7

These securities are directly held by Invus, L.P.

Footnote F8

These securities are directly held by Invus US Partners LLC

Footnote F9

The sole shareholder of Artal Participations S.a r.l. is Artal International S.C.A. The managing partner of Artal International S.C.A. is Artal International Management S.A. The sole stockholder of Artal International Management S.A. is Artal Group S.A. The parent company of Artal Group S.A. is Westend S.A. The majority stockholder of Westend S.A. is Stichting Administratiekantoor Westend (the "Stichting"). Mr. Amaury Wittouck is the sole member of the board of the Stichting.

Footnote F10

The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane.

Footnote F11

The general partner of Avicenna Life Sci Master Fund LP is Avicenna Life Sci Master GP LLC. The managing member of Avicenna Life Sci Master GP LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane.

Footnote F12

The general partner of Invus, L.P. is Invus Advisors, L.L.C. The managing member of Invus Advisors, L.L.C. is Invus Global Management, LLC. The managing member of Invus Global Management, LLC. is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane.

Footnote F13

The managing member of Invus US Partners LLC is Ulys, L.L.C. The managing member of Ulys, L.L.C. is Mr. Raymond Debbane.

Footnote F14

These securities are directly held by Mr. Raymond Debbane.

Footnote F15

Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

SEC remarks

For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.